Pharmacology · Cardiovascular

Fibrates, Niacin, Bile Acid Sequestrants, and Omega-3 Fatty Acids

Visual summary — mechanisms, trial evidence, and clinical roles

Fibrates activate PPAR-alpha to increase lipoprotein lipase expression, reduce ApoC-III (an LPL inhibitor), and suppress hepatic VLDL secretion, making them the primary pharmacological option for severe hypertriglyceridemia above 500 mg/dL where pancreatitis prevention is the primary goal; however, ACCORD-Lipid showed no reduction in cardiovascular events when fenofibrate was added to statin therapy in type 2 diabetes, and PROMINENT confirmed this negative result even with the more potent pemafibrate.
The gemfibrozil-plus-statin combination is absolutely contraindicated because gemfibrozil inhibits both CYP3A4 and the glucuronidation pathway through which statins are normally eliminated, dramatically raising statin plasma concentrations and rhabdomyolysis risk — fenofibrate does not share this interaction and is the safe co-prescribing option.
Niacin raises HDL and lowers triglycerides through receptor-mediated suppression of adipose lipolysis, but both AIM-HIGH and HPS2-THRIVE demonstrated that adding niacin to statin therapy provided no cardiovascular benefit while increasing adverse events including flushing, hyperglycemia, hyperuricemia, and liver toxicity — niacin has been largely abandoned for lipid management in patients already on statins.
Bile acid sequestrants trap bile acids in the gut, forcing the liver to divert cholesterol to bile acid synthesis and upregulating LDL receptors — producing 15 to 25 percent LDL reduction without systemic absorption, making them uniquely safe in children and women of reproductive age; their major clinical limitation is that they bind co-administered medications and must be taken at least one hour before or four to six hours after other drugs.
The critical distinction in omega-3 pharmacology is purity: REDUCE-IT showed that icosapentaenoic acid alone at 4 g/day reduced major adverse cardiovascular events by 25 percent versus mineral oil placebo, while STRENGTH using a mixed EPA/DHA product showed no benefit versus corn oil — the EPA-only formulation (not fish oil supplements) is required for the cardiovascular indication.

Abbreviations: PPAR-alpha = peroxisome proliferator-activated receptor alpha · LPL = lipoprotein lipase · ApoC-III = apolipoprotein C-III · VLDL = very low-density lipoprotein · TG = triglycerides · LDL = low-density lipoprotein · HDL = high-density lipoprotein · MACE = major adverse cardiovascular events · EPA = eicosapentaenoic acid · DHA = docosahexaenoic acid · CYP3A4 = cytochrome P450 3A4

Fibrates — Mechanism, Evidence, and Key Rule

Mechanism

PPAR-alpha Activation

Activate PPAR-alpha transcription factor in liver and muscle
Increase lipoprotein lipase expression → faster VLDL clearance
Reduce ApoC-III (LPL inhibitor) → enhanced triglyceride hydrolysis
Reduce hepatic VLDL secretion
Net effect: TG ↓ 30–50%; HDL ↑ 5–15%; LDL variable

Primary indication

Hypertriglyceridemia & Pancreatitis Prevention

First-line for severe hypertriglyceridemia (TG above 500 mg/dL)
Primary goal: prevent acute pancreatitis
No proven cardiovascular outcome benefit when added to statin therapy
ACCORD-Lipid: no MACE reduction; PROMINENT (pemafibrate): no benefit

Critical interaction

Gemfibrozil — Absolutely Avoid with Statins

Inhibits CYP3A4 and statin glucuronidation → marked statin level increase
Rhabdomyolysis risk dramatically elevated
Contraindicated with all statins
Safe alternative: fenofibrate (does not share this interaction)

Niacin & Bile Acid Sequestrants

Largely abandoned on statins

Niacin (Nicotinic Acid)

Mechanism: activates GPR109A receptor in adipose → reduces free fatty acid flux to liver → less VLDL synthesis
Raises HDL 15–35%; lowers TG 20–50%; modestly lowers LDL
HPS2-THRIVE: no cardiovascular benefit added to statin; increased serious adverse events
Adverse effects: flushing (prostaglandin-mediated; aspirin helps), hyperglycemia, hyperuricemia, hepatotoxicity
No longer recommended in patients on adequate statin therapy

Safe in special populations

Bile Acid Sequestrants

Mechanism: bind bile acids in gut → interrupt enterohepatic circulation → liver uses cholesterol to synthesize more bile acids → LDL receptor upregulation
LDL ↓ 15–25%; TG may increase (avoid in hypertriglyceridemia)
No systemic absorption → safe in children and pregnancy
Drug interaction warning: bind co-administered medications; take other drugs 1 hour before or 4–6 hours after sequestrant
Adverse effects: constipation, bloating, poor palatability

Omega-3 Fatty Acids — The Pure EPA vs Mixed EPA/DHA Distinction

Product	Composition	Key Trial	Result & Clinical Role
Icosapentaenoic acid (Vascepa)	Pure EPA only, 4 g/day	REDUCE-IT (2019)	25% reduction in MACE vs mineral oil placebo; approved for secondary CV prevention + residual hypertriglyceridemia on statin
EPA + DHA (Epanova)	Mixed EPA and DHA, 4 g/day	STRENGTH (2020)	No MACE reduction vs corn oil; trial stopped early for futility
Fish oil supplements (OTC)	Variable; low dose EPA + DHA	VITAL (2019)	No significant MACE reduction in general population; not recommended for cardiovascular prevention

Why Pure EPA Won — Three Proposed Mechanisms

DHA raises LDL-C, which may offset EPA benefit. EPA displaces arachidonic acid from membranes, reducing pro-inflammatory eicosanoids more selectively. EPA also has distinct anti-platelet and plaque-stabilizing effects. The mineral oil placebo used in REDUCE-IT may have mildly raised LDL and hsCRP in the control group, potentially amplifying the apparent benefit — this remains an active debate.

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC.	Mechanism of action of fibrates on lipid and lipoprotein metabolism.	Circulation. 1998;98(19):2088–2093
ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al.	Effects of combination lipid therapy in type 2 diabetes mellitus.	N Engl J Med. 2010;362(17):1563–1574
Das Pradhan A, Glynn RJ, Fruchart JC, et al; PROMINENT Investigators.	Triglyceride lowering with pemafibrate to reduce cardiovascular risk.	N Engl J Med. 2022;387(21):1923–1934
HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al.	Effects of extended-release niacin with laropiprant in high-risk patients.	N Engl J Med. 2014;371(3):203–212
Insull W Jr.	Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.	South Med J. 2006;99(3):257–273
Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators.	Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.	N Engl J Med. 2019;380(1):11–22
Grundy SM, Stone NJ, Bailey AL, et al.	2018 AHA/ACC Guideline on the Management of Blood Cholesterol.	J Am Coll Cardiol. 2019;73(24):e285–e350
Nicholls SJ, Lincoff AM, Garcia M, et al; STRENGTH Trial Investigators.	Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial.	JAMA. 2020;324(22):2268–2280
Mach F, Baigent C, Catapano AL, et al.	2019 ESC/EAS Guidelines for the management of dyslipidaemias.	Eur Heart J. 2020;41(1):111–188
Manson JE, Cook NR, Lee IM, et al; VITAL Research Group.	Marine n-3 fatty acids and prevention of cardiovascular disease and cancer.	N Engl J Med. 2019;380(1):23–32